Company Overview - Becton, Dickinson and Company (BDX) has received CE Mark approval in the European Union for its Revello Vascular Covered Stent, expanding its peripheral vascular portfolio and enhancing its position in the peripheral artery disease (PAD) treatment market [1][3]. Product Details - The Revello Vascular Covered Stent is designed for treating atherosclerotic lesions in the common and external iliac arteries, featuring a self-expanding nitinol stent with an ultrathin expanded polytetrafluoroethylene covering [6][7]. - The device includes a tri-axial delivery system for controlled deployment, an atraumatic tip for smoother insertion, and is available in various diameters and catheter lengths for procedural flexibility [8]. Market Potential - The global peripheral arterial disease treatment market is projected to grow from $3.17 billion in 2025 to approximately $6.11 billion by 2034, with a compound annual growth rate (CAGR) of 7.56% [10]. - The increasing prevalence of PAD among Europe's aging population is expected to drive demand for the Revello stent, allowing BD to capture more procedure volumes and expand its market share [3]. Recent Developments - BD has also received FDA 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system, marking a significant addition to its product offerings [11]. - The company introduced the BD Vacutainer Urine Complete Cup Kit to enhance diagnostic testing efficiency [12]. - BD launched BD Research Cloud 7.0 to advance its AI strategy in flow cytometry and life sciences research [13].